key: cord-0941175-24sxqg5i authors: Baeck, Marie; Herman, Anne title: COVID toes: where do we stand with the current evidence? date: 2020-10-16 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.10.021 sha: 8580839ce6abab25da5c64d2631de1cc27114248 doc_id: 941175 cord_uid: 24sxqg5i BACKGROUND: Numerous of cases of chilblains have been observed, mainly in young subjects with no or mild symptoms compatible with COVID-19. The pathophysiology of these lesions is still widely debated and an association with SARS-CoV-2 infection remains unconfirmed. OBJECTIVES: This paper focus on the unresolved issues about these COVID toes and in particular whether or not they are associated with COVID-19. ARGUMENTS: The temporal link between the outbreak of chilblains and the COVID-19 pandemic is a first suggests a link between the two events. Positive anti-SARS-CoV/SARS-CoV-2 immunostaining on skin biopsy of chilblains seem to confirm the presence of the virus in the lesions, but lack specificity and must be interpreted with caution. Conversely, RT-PCR and anti-SARS-CoV-2 serology were negative in the majority of patients with chilblains. Therefore, SARS-CoV-2 infection can be excluded, with relative certainty, even after accounting for possible lower immunization in mild/asymptomatic patients and for some differences in sensitivity/specificity between the tests used. Some authors hypothesize that chilblains could be the cutaneous expression of a strong type I interferon (IFN-I) response. High production of IFN-I is suggested to be associated with early viral control and may suppress antibody response. However, the absence of other cutaneous or extracutaneous symptoms as observed in other interferonopathies raises unanswered questions. To date, a direct link between chilblains and COVID-19 still seems impossible to confirm. A more indirect association due to lifestyle changes induced by lockdown is a possible explanation. Improvement of chilblains when protective measures were adopted and after lifting of lockdown, support this hypothesis. CONCLUSION: Conflicting current evidence highlights the need for systematic and repeated testing of larger numbers of patients and the need for valid follow-up data that take into consideration epidemic curves and evolution of lockdown measures. -Positive anti-SARS-CoV/SARS-CoV-2 immunostaining on skin biopsy of chilblains seem to confirm the presence of the virus in the lesions, but lack specificity and must be interpreted with caution. -Conversely, RT-PCR and anti-SARS-CoV-2 serology were negative in the majority of patients with chilblains. Therefore, SARS-CoV-2 infection can be excluded, with relative certainty, even after accounting for possible lower immunization in mild/asymptomatic patients and for some differences in sensitivity/specificity between the tests used. -Some authors hypothesize that chilblains could be the cutaneous expression of a strong type I interferon (IFN-I) response. High production of IFN-I is suggested to be associated with early viral control and may suppress antibody response. However, the absence of other cutaneous or extracutaneous symptoms as observed in other interferonopathies raises unanswered questions. -To date, a direct link between chilblains and COVID-19 still seems impossible to confirm. A more indirect association due to lifestyle changes induced by lockdown is a possible explanation. Improvement of chilblains when protective measures were adopted and after lifting of lockdown, support this hypothesis. Conflicting current evidence highlights the need for systematic and repeated testing of larger numbers of patients and the need for valid follow-up data that take into consideration epidemic curves and evolution of lockdown measures. The prevalence of these COVID-toes observed in several European countries but also in the United States is difficult to assess, with some authors drawing attention to possible SALAMI publishing and to overlapping cases reported in scientific literature and social networks (3). These lesions seem to mainly affect feet of children, adolescents and young adults who are otherwise in good health and who have no particular medical history (Fig.1) . However, in our series, blood tests revealed isolated positive anti-nuclear antibodies in one third of patients and these lesions seem to preferentially affect patients with a low BMI (Median:19.13) (4,5). Several patients report symptoms consistent with SARS-CoV-2 infection in the days and weeks prior to the onset of chilblains or contact with people who experienced such symptoms. The discussion focuses on whether or not chilblains are associated with COVID-19: -The temporal link between the outbreak of chilblains and the COVID-19 pandemic (moreover during an unusual season for this type of lesion) is a first argument to suggest a link between the two events. -Some authors have also shown positive anti-SARS-CoV/SARS-CoV-2 immunostaining on skin biopsy specimens of chilblains, which seem to confirm the presence of the virus in the lesions (10, 11) . However, due to lack specificity, these immunostainings should be interpreted with caution. (12, 13) . -Conversely, RT-PCR and anti-SARS-CoV-2 serology were mostly negative (4, 5, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Negative RT-PCR on nasopharyngeal swabs could suggest that chilblains are a late symptom of COVID-19. However, serological tests were often negative. A few publications reported positive serology for anti-SARS-CoV-2 IgA (15, 29) . However, the sensitivity of these antibodies is questionable and it cannot be ruled out that false positives may be due to excessive sensitivity (30) . Negative RT-PCR and serological tests in the majority of patients with chilblains allow to exclude, with relative certainty, SARS-CoV-2 infection, even accounting for possible lower immunization in mild/asymptomatic patients and for some differences in sensitivity/specificity between the tests used. For a viral associated phenomenon, the strikingly low rate of testing positivity raises questions. -Some authors hypothesize that chilblains could be the cutaneous expression of a strong type I interferon (IFN-I) response (31) (32) (33) (34) . A high production of IFN-I is suggested to be associated with early viral control and mild course of SARS-CoV-2 infection. IFN-I may also suppress antibody response which could explain why these patients would not develop J o u r n a l P r e -p r o o f antibodies and fail serologic detection. However, some questions remain unanswered with regard to the sometimes-long delay between the suspected COVID-19 symptoms and the appearance of the skin lesions or the absence of other cutaneous or extracutaneous symptoms as observed in other interferonopathies (35, 36) . -To date, a direct link between chilblains and COVID-19 still seems impossible to confirm. Our study, like others, points towards a more indirect association due to lifestyle changes induced by lockdown, in particular sedentary lifestyles and bare-feet exposure to cool indoors (2, 3, (14) (15) . Patient follow-up support this hypothesis with the observed improvement of chilblains when protective and warm-up measures were adopted and containment restrictions relaxed. It should also be noted that we have observed no new cases of chilblains since lifting of lockdown measures despite recent new infections. Shedding light on unanswered questions would be significant for patient management and information, testing strategies and implementation of isolation measures. Only data on large series of patients with systematic and repeated testing, as well as follow-up information considering epidemic curves and evolution of lockdown measures, will make it possible to strengthen any one hypothesis. Figure Fig 1. Clinical aspect of the COVID toes in an otherwise healthy teenager, with purplisherythematous macules located on the toes Cutaneous Manifestations of COVID-19: An Evidence-Based Review The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries Pitfalls of possible reporting of same patients with COVID-19 in dermatology journals Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic Chilblains and COVID-19: further evidence against a causal association covid toes"): histologic, immunofluorescence and immunohistochemical study of 17 cases Are chilblains a skin expression of COVID-19 microangiopathy? Clinical and Coagulation Characteristics of 7 Patients With Critical COVID-2019 Pneumonia and Acro-Ischemia Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned Perniosis during the COVID-19 pandemic: Negative anti-SARS-CoV-2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS-CoV-2 No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection Major cluster of pediatric " true " primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection Chilblain-like lesions during the COVID-19 pandemic: a serological study on a case series No antibody response in acral cutaneous manifestations associated with COVID-19? Acute acral cutaneous manifestations during the COVID-19 pandemic: a single-centre experience Chilblainlike lesions in pediatrics dermatological outpatients during the COVID-19 outbreak Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries Chilblains in children in the time of Covid-19: new evidence with serology assay Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing COVID-19 and outbreak of chilblains: are they related? Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic All that glisters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions Negative SARS-CoV-2 PCR in patients with chilblain-like lesions Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus When interferon tiptoes through COVID-19: Perniolike lesions and their prognostic implications during SARS-CoV-2 infection Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview Type I interferonopathies: cutaneous vasculopathy, chilblains, panniculitis-induced lipodystrophyand others skin manifestations The patients in this manuscript have given written informed consent for publication of their case details.J o u r n a l P r e -p r o o f